Eli Lilly and Novo Nordisk , whose weight-loss-related drugs have caused a frenzy, are working with the Trump administration on a deal that would cut the cost of the lowest doses of their popular drugs to $149 for a month's supply, people familiar with the matter told The Wall Street Journal.

As part of the deal, which could be announced as soon as Thursday, the drugs would be sold through TrumpRx, a forthcoming government-run initiative expected to launch next year that will connect consumers directly with drug manufacturers to purchase discounted prescription drugs without insurance.

Under the deal, Medicare and Medicaid would also cover the drugs for weight-loss, effectively boosting the number of patients who can access the drug, the people told the Journal.

A Novo Nordisk spokespe

See Full Page